
Curaleaf sets Sebring opening to take Florida footprint to 81 stores
Patient sales are scheduled to begin Nov. 18, ahead of a two-day celebration, while the company reports 191 locations nationwide.

All claims and counterclaims have been dismissed; Geneoscopy says the remaining settlement terms are confidential.

Patient sales are scheduled to begin Nov. 18, ahead of a two-day celebration, while the company reports 191 locations nationwide.

The Kaia agreement ties revenue to secured transactions, while Bitcoin Quantum targets a first-half 2027 mainnet launch.
Drilling is due to start by Nov. 23, but Apollo has disclosed neither a program budget nor a pre-feasibility completion date.
A Korean lead banker is expected shortly, while any listing would require exchange and regulatory approvals.

REGAL recorded median survival of 24.0 months versus 14.7 months on best available treatment, with a biologics filing planned for 2027.

The gold-silver project would require C$604.9 million in initial capital, using US$3,550 gold and US$50 silver.

Public participation will run alongside negotiations and precede any agreement, while Franco-Nevada holds gold and silver stream exposure.

The expanded indication covers procedures performed about 3.5 million times annually in the U.S., extending Hugo beyond urology.
Deliveries from Central Oregon could begin as early as 2030, while the power price, contract term and construction funding remain undisclosed.
The Alberta Growth Connector needs commercial support and approvals; TC Energy disclosed no budget or specific in-service date.
The company reports US$10 million raised through its SATS preferred-share program, with no updated common-share count in the CEO's post.
Private consumption fell 0.3 per cent in July-September, while net exports subtracted 0.6 percentage points from quarterly growth.
Florida regulators counted 170 Trulieve locations on Nov. 6; the new store announcement gives no updated statewide total or first sales date.
Common-share sales and interest income funded the preferred buyback, while the December dividend rate stays at 12 per cent.
FTSE Russell's next list update is Nov. 20, with membership changes scheduled to take effect after the Dec. 11 market close.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The unnamed American aerospace and defence counterparty could acquire rights to half of future output, subject to definitive agreements.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The proposed purchase adds carotid and clot-removal devices, with possible later payments and closing expected in Medtronic's fiscal third quarter.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The proposal would exchange each block of 100 common shares for US$2 cash and preferred stock with a US$24 stated value.
The partners will split development expenses and bank guarantees estimated at NIS334 million, with grid approval still required.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The Financial Times identifies Amazon as the customer, while Fermi says a definitive long-term lease remains under negotiation.

The explorer will reassess working capital needs and financing alternatives after dropping its October offering.

The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The company held C$2.356 million in cash at Sept. 30 and is negotiating a non-binding proposal to acquire a controlling stake in a Polish drone business.

Trading continues on Nasdaq and the TSX as the cannabis producer faces a consecutive-day bid-price test to regain compliance.

International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.